MedTrace Logo

Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis

NCT02780167 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 269

Last updated 2019-05-02

Study results available
· View outcomes & findings →

Summary

Study B7451006 is a Phase 2b POC study which is planned to assess four PF 04965842 once daily (QD) doses (10, 30, 100, 200 mg) relative to placebo over 12 weeks to characterize the efficacy and safety of PF 04965842 in subjects with moderate to severe AD. The objectives of the study are to demonstrate the efficacy of PF 04965842 by showing improvement in disease severity in patients with moderate to severe AD as measured by the Investigator's Global Assessment (IGA) and Eczema Area and Severity Index (EASI) scores, and safety to support further clinical development of PF 04965842.

Conditions

Interventions

DRUG

PF-04965842

10 mg of PF-04965842 QD for 12 weeks

DRUG

PF-04965842

30 mg of PF-04965842 QD for 12 weeks

DRUG

PF-04965842

100 mg of PF-04965842 QD for 12 weeks

DRUG

PF-04965842

200 mg of PF-04965842 QD for 12 weeks

DRUG

Placebo

Placebo QD for 12 weeks

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-04-30
Primary Completion
2017-03-31
Completion
2017-04-30

Countries

  • United States
  • Australia
  • Canada
  • Germany
  • Hungary

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02780167 on ClinicalTrials.gov